• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Ashland (ASH) Could Be 6% Undervalued On New Oral Biologics Launch

    Simply Wall St·09/02/2026 00:28:55
    语音播报

    Ashland (ASH) is drawing fresh attention after launching permexa sodium caprate, an excipient aimed at oral peptide and biologic drugs, including GLP-1 programs, with investors watching how this product could influence its future commercial traction.

    Ashland’s launch of permexa sodium caprate and its upcoming Innovation Day on 17 September 2026 arrive alongside a 32.7% 90 day share price return and 41.7% 1 year total shareholder return, which indicates recent momentum in the stock.

    Scan 19 high quality undiscovered gems that, like Ashland, are pushing new specialty ingredients into high demand drug pipelines and may be building momentum beneath the surface.

    Ashland’s recent 90 day surge and new oral biologics excipient put the spotlight firmly on valuation. After this move, does the current price still offer an appealing balance of risk and potential reward for new capital?

    Most Popular Narrative: 5.7% Undervalued

    The most followed narrative puts Ashland’s fair value at $80.18 against a last close of $75.64, which suggests a modest valuation gap built on detailed long term forecasts.

    The analysts have a consensus price target of $80.18 for Ashland based on their expectations of its future earnings growth, profit margins and other risk factors.

    In order for you to agree with the analysts, you would need to believe that by 2029, revenues will be $2.1 billion, earnings will come to $195.1 million, and it would be trading on a PE ratio of 23.9x, assuming you use a discount rate of 8.0%.

    Read the complete narrative. Read the complete narrative.

    Want to see what sits behind that $80.18 fair value for Ashland? The story hinges on a specific path for revenue, margin recovery and the earnings multiple. Curious which assumptions really carry the model and how much growth is reflected versus profitability gains? The full narrative lays out those moving parts in one place.

    Result: Fair Value of $80.18 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, Ashland’s story can change quickly if demand in key regions remains weak or if further portfolio reshaping keeps overall revenue growth subdued.

    Find out about the key risks to this Ashland narrative.

    Another View: Ashland Through Earnings Multiples

    The SWS DCF model points to Ashland trading below estimated future cash flow value at $75.64 versus a $100.55 fair value, which frames the stock as undervalued. That is a much larger gap than the 5.7% narrative discount. Which signal should be treated as more important?

    Look into how the SWS DCF model arrives at its fair value.

    ASH Discounted Cash Flow as at Sep 2026
    ASH Discounted Cash Flow as at Sep 2026

    Next Steps

    After weighing Ashland’s recent momentum and differing fair value signals, it makes sense to move fast, review the data and decide where you sit. To see both sides of the story in one place, start with the 3 key rewards and 2 important warning signs.

    Looking for more investment ideas beyond Ashland?

    If you stop with Ashland, you risk missing other stocks that might fit your goals even better, so use the screener to widen your opportunity set.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.